The question of whether pregnancy influences HIV type 1 disease progression has been the subject of several investigations.^[@R1]--[@R15]^ However, very limited information is available on the effects of pregnancy in response to antiretroviral therapy (ART). There are several mechanisms by which pregnancy may affect response to ART, both biologic and behavioral, that can affect drug intake and adherence. Pregnancy related physiological changes may affect absorption, distribution, metabolism, or excretion of drugs.^[@R16]^ Pregnancy may also alter immune responses.^[@R17]^

Information on potential effects of incident pregnancy in response to ART is particularly relevant for resource-limited settings, as plans for ART rollout among all HIV-infected women of reproductive age are currently in progress in many such countries. The few studies addressing this question from sub-Saharan African settings have led to differing conclusions of either no change in risk or of increased risk of virologic failure on ART with pregnancy.^[@R18]--[@R21]^ Studying the effects of pregnancy in response to ART has, nonetheless, great importance for policy, particularly with regards to counseling HIV-infected women who are on ART about their fertility desires and subsequent family planning or optimizing prepregnancy health.

We examined whether pregnancy affects response to ART among HIV-infected women followed in 3 prospective studies of HIV-serodiscordant couples in Africa.

METHODS {#s1}
=======

Study Population {#s1-1}
----------------

Enrollment and follow-up for the Partners in Prevention Herpes simplex virus (HSV)/HIV Transmission Study (2004--2008), the Couples Observational Study (2008--2010), and the Partners Preexposure Prophylaxis (PrEP) Study (2008--2013) has been previously described.^[@R22]--[@R27]^ Briefly, HIV-serodiscordant heterosexual couples from 7 African countries (Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia) were enrolled and followed between 2004 and 2013. Overall in 63% of couples, the HIV-infected partner was female. At the time of enrollment, HIV-infected partners did not meet national guideline eligibility criteria for ART use; during follow-up, clinical and immunologic status was monitored and ART was recommended and initiated according to national guidelines.

Demographic information was collected at enrollment, whereas data on ART use were collected quarterly with follow-up continuing for a maximum of 1 year (Couples Observational Study), 2 years (Partners in Prevention HSV/HIV Transmission Study), or 3 years (Partners PrEP Study). CD4^+^ T-cell counts were measured every 6 months; HIV viral load (VL) was measured every 6 months in the Partners in Prevention Study and Couples Observational Study and annually in the Partners PrEP Study. Pregnancy status was ascertained at each study visit by history; urine pregnancy tests were performed quarterly in the Partners in Prevention HSV/HIV Transmission Study and as clinically indicated in the other 2 studies. Date of last menstrual period (LMP), estimated date of delivery, and pregnancy information were collected with standardized questionnaires. All women gave written informed consent. The studies were approved by the University of Washington Human Subjects Review Committee and local ethic review boards at each study site.

Statistical Analysis {#s1-2}
--------------------

For this analysis, women were included if they (1) were enrolled as the HIV-infected partner in the HIV-serodiscordant couple, (2) were started on ART during study follow-up, (3) were not pregnant at the time of ART initiation, (4) were aged 45 years or younger, and (5) had at least one study visit at which plasma was obtained for HIV VL assessment after starting ART (N = 1041). Pregnancies prevalent at the time of ART initiation were excluded, as many pregnant women are started on ART to prevent mother-to-child transmission of HIV, and not for their own clinical indications. The exposure was pregnancy occurring after ART initiation, defined as a time-dependent variable, which could include multiple pregnancies occurring after ART initiation. Start of pregnancy was defined as the date of LMP and the end of pregnancy as the date of delivery or pregnancy loss. Complete data on LMP and date of delivery were available for 96% of pregnancies; for the remaining pregnancies, start and end dates were estimated using the reported duration of the pregnancy based on maternal history and either the LMP or date of delivery. Virologic failure was defined as plasma HIV RNA greater than 400 copies per milliliter 6 months or later after ART initiation. This included both failure to achieve virologic suppression within 6 months of initiating ART and virologic rebound after initial suppression. To meet this outcome, women had to have at least one plasma HIV VL result 6 months or later after ART initiation (n = 769).

We compared baseline characteristics between women who became pregnant after ART initiation and those who did not using Wilcoxon rank-sum tests or χ^2^ tests. Multivariable Cox proportional hazards models stratified by study and extended Kaplan--Meier curves^[@R28]^ were used to assess the effect of incident pregnancy after ART initiation on time to virologic suppression (HIV VL ≤400 copies per milliliter), time to virologic failure, time to World Health Organization (WHO) clinical stage III or IV, and time to death. Linear mixed-effects models were used to assess the effect of time-varying incident pregnancy on CD4^+^ T-cell count and plasma HIV VL after ART initiation. Age, study year, education, income, marital status, parity, CD4^+^ T-cell count before ART initiation, HIV VL before ART initiation, and diagnosis of tuberculosis at ART initiation were considered as potential confounders, and were included in final models if the hazard ratio for incident pregnancy changed by greater than 10%. All analyses were conducted in SAS 9.3 (SAS Institute, Cary, NC).

RESULTS {#s2}
=======

Participant Characteristics {#s2-1}
---------------------------

Among the 1041 women included in this analysis, most (81.2%) were enrolled in the Partners PrEP Study. The great majority (95.7%) were married, whereas about half reported any monthly income (Table [1](#T1){ref-type="table"}). Their median age was 32 years, median duration of education was 7 years, and median number of children was 2 (Table [1](#T1){ref-type="table"}). The median CD4^+^ T-cell count before ART initiation was 276 cells per cubic millimeter (interquartile range \[IQR\], 209--375 cells per cubic millimeter), and the median HIV VL before ART initiation was 17,511 copies per milliliter (IQR, 2480--69,286 copies per milliliter). Approximately 5% had a diagnosis of or had been treated for tuberculosis at ART initiation (Table [1](#T1){ref-type="table"}). The most common first-line ART regimens included zidovudine or stavudine or tenofovir, lamivudine, and nevirapine or efavirenz.
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Baseline Characteristics for 1041 HIV-Infected Women Included in the Analysis, by Pregnancy Status After Initiating ART
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Effect of Pregnancy in Response to ART {#s2-2}
--------------------------------------

The 1041 women contributed 1196.1 person-years of follow-up, with a median follow-up time of 1.0 year (IQR, 0.6--1.7). One hundred ten women (10.6%) became pregnant at least once after ART initiation. Women who became pregnant were younger (median age, 29 vs. 33 years, *P* \< 0.001) and less likely to have any monthly income (41.8% vs. 52.1%, *P* = 0.04) than those who did not become pregnant (Table [1](#T1){ref-type="table"}). Overall, the proportion of women achieving viral suppression was 82.9%; virologic failure occurred in 24.7% of women, 5.9% progressed to WHO clinical stage III or IV, and 1.2% died. Pregnancy was not associated with time to viral suppression (adjusted hazard ratio, \[aHR\], 1.20, 95% confidence interval \[CI\]: 0.82 to 1.77), time to virologic failure (aHR, 0.67, 95% CI: 0.37 to 1.22), time to WHO clinical stage III or IV (aHR, 0.79, 95% CI: 0.19 to 3.30), or time to death (aHR, 2.04, 95% CI: 0.25 to 16.8) (Table [2](#T2){ref-type="table"}). The median time to viral suppression for those who became pregnant was 4.29 months compared with 4.26 months for those who did not become pregnant. Incident pregnancy was associated with an adjusted mean decrease in CD4^+^ T-cell count of 47.3 cells per cubic millimeter (*P* \< 0.001), but not with difference in HIV plasma VL (*P* = 0.06) (Tables [3](#T3){ref-type="table"} and Fig. [1](#F1){ref-type="fig"}).
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Associations Between Incident Pregnancy and Clinical/Virologic Outcomes After Initiation of ART: The Couples Observational Study, the Partners in Prevention Study, and the Partners PrEP Study
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Associations Between Incident Pregnancy and CD4^+^ T-Cell Count and Plasma HIV VL After Initiation of ART: The Couples Observational Study, the Partners in Prevention Study, and the Partners PrEP Study
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![CD4^+^ T-cell count (A) and Plasma HIV VL (B) from initiation of ART by time-varying incident pregnancy.](qai-74-38-g004){#F1}

Because the studies did not have information about attendance at clinical care visits outside the research clinics, we used study retention as a proxy to evaluate overall compliance with care. This was to see whether any differences by pregnancy status may be explained by differences in follow-up, additional testing, and care of pregnant women compared with nonpregnant women. There was no difference in the odds of attendance at the next regular study visit between pregnant and nonpregnant women (odds ratio, 0.79, 95% CI: 0.59 to 1.06).

DISCUSSION {#s3}
==========

In this analysis of prospective data from HIV-infected women who initiated ART in 7 African countries, we found that incident pregnancy after ART initiation was not associated with a delay in time to virologic suppression, increased risk of virologic failure of therapy during follow-up, or increased risk of clinical progression of HIV disease to WHO clinical stage III or IV, or death. A modest decrease of CD4^+^ T-cell count was seen among those with incident pregnancies (mean decrease of 47.7 cells per cubic millimeter compared with nonpregnant women) over the course of follow-up.

Pregnancy-induced changes in the immune system may increase susceptibility to and severity of infectious diseases.^[@R29]^ Although most evidence does not support a role for pregnancy in accelerating HIV disease progression, mainly from studies from the United States and Europe,^[@R2]--[@R4],[@R7]--[@R15]^ some data from developing countries have suggested progression of HIV disease in pregnancy.^[@R5],[@R6]^ Differences in the impact of pregnancy on HIV disease across geographic areas may reflect differences in other concomitant factors, such as poverty, nutrition, concurrent infections, or stage of HIV disease at the time of pregnancy.

Limited information is available about the effects of pregnancy in response to ART. Physiologic changes during pregnancy are multifaceted and may be compounded by the introduction of ART. When a meta-analysis of studies on pregnancy and HIV disease progression published through 2013 was stratified by ART availability, the pooled estimates for the effect of pregnancy on accelerating progression to low CD4^+^ T-cell count, HIV-related illness, AIDS-defining illness, and death were attenuated when ART was available, with significant effect modification by ART availability on the effects of pregnancy on AIDS-defining illness and death.^[@R1]^ For most of these studies, ART, if available, was initiated during pregnancy. Data on the effect of incident pregnancy among women already taking ART are even more limited. It is however important to make this distinction, as women who initiate ART during pregnancy do so mainly for prevention of mother-to-child transmission and are more likely to be healthier, whereas women who are on ART when they become pregnant are more likely to have initiated ART for their own immunologic or clinical indications. In a single study with the primary aim of evaluating incident pregnancy on clinical HIV disease progression among HIV-infected women who became pregnant in South Africa, incident pregnancy after ART initiation was not associated with an increased hazard of a new AIDS event or death.^[@R30]^

Unlike our study\'s findings of no effect of incident pregnancy on virologic failure, a study of 541 pregnancies during follow-up of 5954 women in South Africa found incident pregnancy after combination ART initiation was associated with a modest increase in risk of virologic failure (aHR, 1.34, 95% CI: 1.02 to 1.78).^[@R18]^ That study\'s strength was its large sample size and careful statistical analysis; however, it was based on analysis of observational data from a single clinic\'s database that lacked baseline HIV VL for most women, and confounding cannot be ruled out. In 3 much smaller studies, there was no evidence of an effect of incident pregnancy on HIV RNA change or virologic failure.^[@R19]--[@R21]^ The largest of these studies was among 128 women who became pregnant after 3 or more months of combination ART in the Swiss Mother and Child HIV Cohort Study, which found no difference in the frequency of virologic failure during pregnancy compared with a period of equal duration before and after pregnancy (adjusted odds ratio = 1.04, 95% CI:0.48 to 2.28).^[@R20]^

Our finding of a modest decrease of the CD4^+^ T-cell count among women with incident pregnancies (mean decrease of 47.7 cells per cubic millimeter) was not unexpected. Cellular immunity and CD4^+^ lymphocyte levels are expected to decline during pregnancy in all women but eventually return to prepregnancy levels.^[@R31]^ In a pooled analysis of 4 studies,^[@R3],[@R9],[@R11],[@R12]^ HIV-infected pregnant women exposed to no or partial ART had marginally increased risk (1.41, 95% CI: 0.99 to 2.02) of progressing to a low CD4^+^ T-cell count compared with nonpregnant HIV-infected women.^[@R1]^ Although these studies counted the postpartum period in the pregnancy person-time, other studies have compared the prepregnancy, pregnancy, and postpartum periods and found that CD4^+^ T-cell count declines during pregnancy are temporary effects, likely due to physiologic effects of pregnancy, and rebound in the postpartum period.^[@R15],[@R19]^

Our analysis has some limitations. The follow-up time was not long enough to allow separate evaluation of pregnancy versus any postpartum effects. As most of the women were on a standard first-line ART regimen, we were also unable to examine possible effects of pregnancy in response to different ART regimens. Despite our relatively large sample size, the power of this study to detect small effects of pregnancy in response to ART may be limited. Strengths of our study include the prospective, systematic, and detailed data collection across all clinical study participants, statistical analysis to account for time-varying variables, and recruitment from several countries in Africa, which may enhance generalizability of the results.

Rapid adoption of the WHO\'s recommendation of lifelong ART for all pregnant and breastfeeding women living with HIV regardless of CD4^+^ T-cell count or clinical stage of disease has led to large increases in the proportion of HIV-infected pregnant women using and seeking ART. Moreover, with the recommendation of maintaining ART for life and the low risk of HIV transmission to their infants when HIV viremia is suppressed, more women will remain healthy and experience repeat incident pregnancies while using ART. Indeed, emerging data suggest that use of ART is associated with heightened feelings of hope, health, fertility desires, and a 70% higher rate of subsequent pregnancy.^[@R32]--[@R35]^ It is thus important to understand how pregnancy may affect a woman\'s response to ART. Our findings add to the emerging body of evidence that incident pregnancy does not seem to affect virologic, immunologic, and clinical response to ART. These findings have implications for counseling HIV-infected women of reproductive age who desire pregnancy about the potential for a healthy pregnancy and child when ART is used. However, intensive counseling about the importance of antenatal and postnatal adherence to ART for the mothers\' and infant\'s health and continued careful monitoring of long-term clinical outcomes for both women and their infants is important.
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